Browse
Explore conditions, clinical trials, and the organisations running them.
Find a trial
Search by condition, then narrow by status and aim.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
137755 trials found · Page 3 of 6888
-
CRISPR-Based gene editing tested as One-Time fix for inherited emphysema
Cure Not yet recruitingA Study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD).
Phase 1/2 • Sponsor: CRISPR Therapeutics • Aim: Cure
Last updated Oct 02, 2026 00:00 UTC
-
Can a Sibling's bone marrow cure sickle cell disease in children?
Cure OngoingThis study aims to enroll 58 pre-adolescent (\<13 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor. All participants will go through a pre-transplant evaluation to find out if there are health problems that will keep…
Phase 2 • Sponsor: Emory University • Aim: Cure
Last updated Sep 26, 2026 00:00 UTC
-
Can a new liver cure cancer that has spread? trial tests transplant for colorectal metastases
Cure OngoingPatients with unresectable liver metastases (LM) from colorectal cancer (CRC)have a poor prognosis. In patients with resectable disease, surgery offers a distinct survival benefit. This study will offer live donor liver transplantation (LDLT) to select patients with unresectable …
Sponsor: University Health Network, Toronto • Aim: Cure
Last updated Oct 04, 2026 00:00 UTC
-
Cancer drug tested against deadly infant heart disease
Disease control Not yet recruitingThis project seeks to perform a Phase 3 clinical trial to test whether an FDA-approved cancer drug called trametinib is effective in treating young infants with genetic conditions called RASopathies and a severe, life-threatening heart problem called hypertrophic cardiomyopathy. …
Phase 3 • Sponsor: Carelon Research • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Stem cells through the nose: a shot at stopping cerebral palsy
Cure Not yet recruitingHypoxic-ischemic brain injury (HIBI) is a leading cause of death and lifelong disability in near-term and term infants, most often caused by perinatal arterial ischemic stroke (PAIS, incidence approximately 1:5000 live births) or perinatal asphyxia (PA, incidence 1-2:1000 live bi…
Phase 2/3 • Sponsor: UMC Utrecht • Aim: Cure
Last updated Sep 23, 2026 00:00 UTC
-
Replacing the whole liver: a radical bid to outlast colorectal cancer
Cure Not yet recruitingPatients whose colorectal cancer has spread to the liver, and whose liver metastases cannot be removed by surgery or destroyed by ablation, currently receive palliative chemotherapy in Germany. Fewer than one in ten of these patients survive five years. International studies have…
Sponsor: Charite University, Berlin, Germany • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can a stem cell transplant reset the immune system in children with severe arthritis?
Cure Recruiting nowThe goal of this study is to collect clinical data and samples and to evaluate the feasibility of allogeneic hematopoietic cell transplantation (HCT) in children and young adults with refractory Systemic Juvenile Idiopathic Arthritis (sJIA), including those with sJIA-associated l…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Cure
Last updated Oct 01, 2026 00:00 UTC
-
New injection tested to prevent heart attacks and strokes in High-Risk patients
Prevention Not yet recruitingThis clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo. The purpose of this clinical study is to find out if zenagamtide is safe and …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Prevention
Last updated Oct 08, 2026 00:00 UTC
-
Ring vaccination trial aims to stop a deadly ebola relative
Vaccine Not yet recruitingBundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed. There is an urgent need to identify vaccines that are safe, immunogenic, and effective in preventing disease among people at highest risk of inf…
Phase 2/3 • Sponsor: Jean-Pierre Van geertruyden • Aim: Vaccine
Last updated Oct 07, 2026 00:00 UTC
-
Gene editing shot aims to permanently lower bad cholesterol
Disease control Not yet recruitingThe purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Phase 2 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated Sep 26, 2026 00:00 UTC
-
Muscle-Injected gene therapy aims to help type 1 diabetes control blood sugar
Cure Recruiting nowThis study is testing VV-14300 in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system. VV-14300 is an investigational gene therapy that is injected into muscle and is designed to help re…
Phase 1/2 • Sponsor: Kriya Therapeutics, Inc. • Aim: Cure
Last updated Oct 07, 2026 00:00 UTC
-
Off-the-Shelf donor cells target two markers on Hard-to-Treat leukemia
Cure Recruiting nowThe purpose of this phase I/II clinical trial is to test CARCIK-CD123/33 cells to treat patients with R/R AML/BPDCN, who have otherwise exhausted conventional treatment options. In particular, this study will assess the safety and feasibility of CARCIK-CD123/33 cells infusion in …
Phase 1/2 • Sponsor: Fondazione Matilde Tettamanti Menotti De Marchi Onlus • Aim: Cure
Last updated Oct 18, 2026 00:00 UTC
-
Can two antibodies and a cancer drug free people with HIV from daily pills?
Cure Not yet recruitingAntiretroviral therapy (ART) has significantly extended the life expectancy of people living with HIV-1 (PLWH), but it does not cure the infection. Broadly neutralizing antibodies (bNAbs), such as 3BNC117 and 10-1074, not only neutralize circulating virus but also engage the immu…
Phase 2 • Sponsor: Ole Schmeltz Søgaard • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Can engineered immune cells reset the body in Hard-to-Treat autoimmune diseases?
Cure Recruiting nowAutoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage. Autoimmune diseases encompass a wide variety of conditions, such as systemic lupus erythematosus(SLE), Sjögren's syndrome (SS), systemic scl…
Phase 1/2 • Sponsor: Peking University Third Hospital • Aim: Cure
Last updated Sep 24, 2026 00:00 UTC
-
Can checkpoint inhibitors help the immune system clear hepatitis b?
Cure Recruiting nowHepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of HBV treatment. However, HBsAg loss can be achieved…
Phase 2 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Cure
Last updated Sep 30, 2026 00:00 UTC
-
Bone drug denosumab tested as breast cancer shield for BRCA1 carriers
Prevention OngoingThis phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Prevention
Last updated Oct 07, 2026 00:00 UTC
-
Engineered immune cells aim to wipe out stubborn leukemia
Cure Recruiting nowThis is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
Phase 2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
One-Time gene therapy aims to restore dystrophin in duchenne
Cure Recruiting nowGNT0004 is a recombinant adeno-associated viral (AAV) vector gene therapy composed of an AAV8 serotype capsid containing a sequence-optimized gene for a human microdystrophin. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder caused by dystrophin gene mutations leadin…
Phase 2/3 • Sponsor: Genethon • Aim: Cure
Last updated Oct 15, 2026 00:00 UTC
-
Engineered t cells target childhood tumors in early trial
Cure OngoingThe purpose of this study is to test the safety and efficacy of GD2-CART01, a CAR T cell treatment targeting GD2 in paediatric or young adult patients with High Risk and/or relapsed/refractory Neuroblastoma. A small exploratory cohort of patients with GD2-positive tumors other t…
Phase 1/2 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Cure
Last updated Oct 02, 2026 00:00 UTC
-
Can an Immune-Boosting drug stop lung cancer from returning?
Prevention CompletedThe purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC